Citi raised the firm’s price target on Kymera Therapeutics (KYMR) to $60 from $52 and keeps a Buy rating on the shares. Positive Phase 1 healthy volunteer data for KT-621 de-risks the asset and underscores the potential of Kymera’s platform, the analyst tells investors. The firm believes this potent efficacy, clean safety, and promising biomarker data, though in healthy volunteers, “strongly derisks” KT-621 and Citi increased its view of the odds of success for KT-621 to 15% from 10% and now models peak 2030 sales of $520M, the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics upgraded to Buy at BofA after KT-621 data
- Kymera Therapeutics upgraded to Buy from Neutral at BofA
- Oppenheimer bullish on Nurix as Sanofi opt-in, competitor data derisk STAT6
- Kymera Therapeutics Discusses Phase 1 Study Results
- Kymera Therapeutics Announces Positive Phase 1 Study Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue